Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sawai Pharmaceutical Co. Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active matters are split between 2 distinct examiners. Furthermore, the portfolio spans 2 distinct art units, which indicates that the company's pharmaceutical innovations are being reviewed across different specialized divisions within the USPTO.
The busiest examiner identified in the data is ATKINSON, JOSHUA ALEXANDER, who is managing 1 pending office action. Given that there are 2 pending office actions in total, the workload is split between the distinct examiners. This distribution suggests that the company's prosecution efforts are not concentrated under a single individual but are instead diversified across different examiners and art units.
For a patent practitioner, the presence of 2 distinct art units for the active matters suggests that the subject matter may be diverse or multidisciplinary within the Biotechnology & Pharmaceuticals field. Monitoring the 2 distinct examiners requires tracking separate sets of examiner statistics and preferences. This structure necessitates a versatile prosecution approach to accommodate the different standards that may exist between the art units involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17941129 | FILM-COATED GRANULE, PHARMACEUTICAL PREPARATION CONTAINING THE SAME, AND MANUFACTURING METHODS THEREOF | KASSA, TIGABU | 3d overdue |
| 17942594 | GRANULES AND PREPARATION USING SAME | ATKINSON, JOSHUA ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17942594 | GRANULES AND PREPARATION USING SAME | ATKINSON, JOSHUA ALEXANDER | 1612 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17941129 | FILM-COATED GRANULE, PHARMACEUTICAL PREPARATION CONTAINING THE SAME, AND MANUFACTURING METHODS THEREOF | KASSA, TIGABU | 1619 | §103 | Final Rejection | 3d overdue | Pending | Sep 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial